SK Capital completes sale of Noramco, Extractas Biosciences and Purisys to Siegfried Holding

SK Capital will retain ownership of Halo Pharmaceuticals, a finished-dose-form CDMO in the US and Canada.

4 May 2026•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.